7th Eurasian Hematology Oncology Summit
How I Treat CLL in 2020: How Do Ibrutinib/Rituximab & Venetoclax/Obinutuzumab Combinations Affect PFS? What Parameters Should Be Used to Guide the Treatment?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Robin Foa
By
7th Eurasian Hematology Oncology Summit
FEATURING
Robin Foa
Login to view comments.
Click here to Login
